Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

NBIX

Neurocrine Biosciences (NBIX)

Neurocrine Biosciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NBIX
DateTimeSourceHeadlineSymbolCompany
24/01/202508:05PR Newswire (US)Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and DeviceNASDAQ:NBIXNeurocrine Biosciences Inc
22/01/202508:05PR Newswire (US)Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & MetabolismNASDAQ:NBIXNeurocrine Biosciences Inc
18/01/202508:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
16/01/202508:19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
09/01/202500:30PR Newswire (US)Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & MetabolismNASDAQ:NBIXNeurocrine Biosciences Inc
07/01/202508:01PR Newswire (US)Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:NBIXNeurocrine Biosciences Inc
04/01/202508:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
01/01/202508:17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
21/12/202400:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBIXNeurocrine Biosciences Inc
21/12/202400:00PR Newswire (US)Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal HyperplasiaNASDAQ:NBIXNeurocrine Biosciences Inc
20/12/202408:47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
20/12/202408:37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
18/12/202408:29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
14/12/202410:55PR Newswire (US)Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal HyperplasiaNASDAQ:NBIXNeurocrine Biosciences Inc
04/12/202410:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
30/11/202405:41Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
27/11/202408:01PR Newswire (US)Neurocrine Biosciences to Participate at Investor Conferences in DecemberNASDAQ:NBIXNeurocrine Biosciences Inc
13/11/202409:58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
08/11/202411:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
08/11/202400:30PR Newswire (US)Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) CapsulesNASDAQ:NBIXNeurocrine Biosciences Inc
06/11/202408:01PR Newswire (US)Neurocrine Biosciences to Participate at Investor Conferences in NovemberNASDAQ:NBIXNeurocrine Biosciences Inc
05/11/202400:30PR Newswire (US)Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) CapsulesNASDAQ:NBIXNeurocrine Biosciences Inc
05/11/202400:25PR Newswire (US)Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive DyskinesiaNASDAQ:NBIXNeurocrine Biosciences Inc
02/11/202410:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
01/11/202423:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBIXNeurocrine Biosciences Inc
30/10/202422:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NBIXNeurocrine Biosciences Inc
30/10/202422:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBIXNeurocrine Biosciences Inc
30/10/202422:00PR Newswire (US)Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales GuidanceNASDAQ:NBIXNeurocrine Biosciences Inc
12/10/202407:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBIXNeurocrine Biosciences Inc
10/10/202407:01PR Newswire (US)Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial ResultsNASDAQ:NBIXNeurocrine Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:NBIX

Your Recent History

Delayed Upgrade Clock